TerrAscend (TSNDF) Cash from Financing Activities (2021 - 2026)
TerrAscend's (TSNDF) quarterly Cash from Financing Activities came in at -$7.1 million in Q1 2026, down 205.44% year-on-year from $6.8 million in Q1 2025, and down 22.63% on a QoQ basis from -$5.8 million in Q4 2025.
TerrAscend (TSNDF) Cash from Financing Activities (2021 - 2026) Analysis & Trends
TerrAscend (TSNDF) has 6 years of Cash from Financing Activities data on file, last reported at -$7.1 million in Q1 2026.
- On a quarterly basis, Cash from Financing Activities fell 205.44% year-over-year to -$7.1 million in Q1 2026; TTM through Mar 2026 was -$609000.0, a 96.51% increase from a year earlier, with the FY2025 full-year figure at $4.2 million, up 116.94% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$7.1 million, down from -$5.8 million in the prior quarter.
- Over the last five years, Cash from Financing Activities for TSNDF reached as high as $17.1 million in Q1 2022 and fell as low as -$15.1 million in Q4 2023.
- Historically, Cash from Financing Activities has averaged -$2.1 million across 5 years, with a median of -$4.4 million in 2024.
- Across the five-year window, Cash from Financing Activities plunged 728.16% in 2023 and surged 283.0% in 2025, its largest moves.
- Year by year, Cash from Financing Activities stood at -$1.8 million in 2022, then plunged by 728.16% to -$15.1 million in 2023, then soared by 70.78% to -$4.4 million in 2024, then tumbled by 32.18% to -$5.8 million in 2025, then fell by 22.63% to -$7.1 million in 2026.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were -$7.1 million in Q1 2026, -$5.8 million in Q4 2025, and $9.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -1.48 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -65.00 Mn |
| 10 | TerrAscend | 160.44 Mn | 162.98 Mn | 34.60 Mn | -7.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.13 Mn |
| Mar 31, 2026 | -7.13 Mn |
| Dec 31, 2025 | -5.82 Mn |
| Dec 31, 2025 | -5.82 Mn |
| Sep 30, 2025 | 9.72 Mn |
| Sep 30, 2025 | 9.72 Mn |
| Jun 30, 2025 | 2.62 Mn |
| Jun 30, 2025 | 2.62 Mn |
| Mar 31, 2025 | -2.34 Mn |
| Mar 31, 2025 | -2.34 Mn |
| Dec 31, 2024 | -4.40 Mn |
| Dec 31, 2024 | -4.40 Mn |
| Sep 30, 2024 | -5.31 Mn |
| Sep 30, 2024 | -5.31 Mn |
| Jun 30, 2024 | -5.41 Mn |
| Jun 30, 2024 | -5.41 Mn |
| Mar 31, 2024 | -9.60 Mn |
| Mar 31, 2024 | -9.60 Mn |
| Dec 31, 2023 | -15.06 Mn |
| Dec 31, 2023 | -15.06 Mn |